Malaria vaccines and the new malaria agenda

Clinical Microbiology and Infection

Volumn 17, Issue 11, 2011, Pages 1600-1607

  Greenwood, B M ^a   Targett, G A T ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Malaria; Malaria eradication; Malaria transmission; Polymorphism; Vaccines

Indexed keywords

ADENOVIRUS VECTOR; CHLOROQUINE; CIRCUMSPOROZOITE PROTEIN; DNA VACCINE; ERYTHROCYTE ANTIGEN; ERYTHROCYTE MEMBRANE PROTEIN 1; HEPATITIS B SURFACE ANTIGEN; MALARIA VACCINE; PARASITE ANTIGEN; VIRUS VECTOR;

ANTIBODY PRODUCTION; ANTIBODY RESPONSE; BIOASSAY; CELL ACTIVATION; CLINICAL DEVELOPMENT PLAN; CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; DISEASE TRANSMISSION; DRUG COST; ERYTHROCYTE; FERTILITY; GAMETOCYTE; GENETIC VARIABILITY; HEMOGLOBINOPATHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; IN VITRO STUDY; LEUKOCYTE; LIFESPAN; MALARIA; MALARIA CONTROL; MALARIA FALCIPARUM; MENINGOCOCCOSIS; MORBIDITY; MORTALITY; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PLASMODIUM (LIFE CYCLE STAGE); PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM; PLASMODIUM GALLINACEUM; PLASMODIUM KNOWLESI; PLASMODIUM MALARIAE; PLASMODIUM OVALE; PLASMODIUM VIVAX; PNEUMOCOCCAL INFECTION; PREGNANT WOMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; T LYMPHOCYTE; TISSUE INJURY; ULTRAVIOLET IRRADIATION; VACCINATION;

EID: 80054056017     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2011.03612.x     Document Type: Review

References (55)

1. O'Meara WP, Mangeni JN, Steketee R, Greenwood B. Changes in the burden of malaria in sub-Saharan Africa. Lancet Infect Dis 2010; 10: 545-555.
2. World Health Organization. World Malaria Report 2010. Geneva: WHO, 2010.
3. Crompton PD, Pierce SK, Miller LH. Advances and challenges in malaria vaccine development. J Clin Invest 2010; 120: 4168-4178.
4. Snow RW, Marsh K. Malaria in Africa: progress and prospects in the decade since the Abuja Declaration. Lancet 2010; 376: 137-139.
5. White NJ. Artemisinin resistance-the clock is ticking. Lancet 2010; 376: 2051-2052.
6. World Health Organization. The technical basis for co-ordinated action against insecticide resistance: preserving the effectiveness of modern malaria vector control. Geneva: WHO, 2011.
7. Feachem RG, Phillips AA, Hwang J et al. Shrinking the malaria map: progress and prospects. Lancet 2010; 376: 1566-1578.
8. Freund J, Thomson KJ, Sommer HE, Walter AW, Pisani TM. Immunization of monkeys against malaria by means of killed parasites with adjuvants. Am J Trop Med Hyg 1948; 28: 1-22.
9. Targett GA, Fulton JD. Immunization of rhesus monkeys against Plasmodium knowlesi malaria. Exp Parasitol 1965; 17: 180-193.
10. Singh B, Kim Sung L, Matusop A et al. A large focus of naturally acquired Plasmodium knowlesi infections in human beings. Lancet 2004; 363: 1017-1024.
11. Drakeley C, Sutherland C, Bousema JT, Sauerwein RW, Targett GA. The epidemiology of Plasmodium falciparum gametocytes: weapons of mass dispersion. Trends Parasitol 2006; 22: 424-430.
12. PATH/MVI. Malaria vaccine technology roadmap. Available at: (last accessed 1 July 2011).
13. Sinden RE. A biologist's perspective on malaria vaccine development. Hum Vaccin 2010; 6: 3-11.
14. Sherman IW. The elusive malaria vaccine: miracle or mirage. Washington: ASM Press, 2009.
15. Nussenzweig RS, Vanderberg J, Most H, Orton C. Protective immunity produced by the injection of X-irradiated sporozoites of Plasmodium berghei. Nature 1967; 216: 160-162.
16. Clyde DF. Immunization of man against falciparum and vivax malaria by use of attenuated sporozoites. Am J Trop Med Hyg 1975; 24: 397-401.
17. Casares S, Brumeanu TD, Richie TL. The RTS, S malaria vaccine. Vaccine 2010; 28: 4880-4894.
18. Olotu A, Lusingu J, Leach A et al. Efficacy of RTS, S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial. Lancet Infect Dis 2011; 11: 102-109.
19. Hoffman SL, Billingsley PF, James E et al. Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hum Vaccin 2010; 6: 97-106.
20. Vaughan AM, Wang R, Kappe SH. Genetically engineered, attenuated whole-cell vaccine approaches for malaria. Hum Vaccin 2010; 6: 107-113.
21. VanBuskirk KM, O'Neill MT, De La Vega P et al. Preerythrocytic, live-attenuated Plasmodium falciparum vaccine candidates by design. Proc Natl Acad Sci USA 2009; 106: 13004-13009.
22. Roestenberg M, Teirlinck AC, McCall MB et al. Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study. Lancet 2011; 377: 1770-1776.
23. Greenwood B, Targett G. The mysteries of immunity to malaria. Lancet 2011; 377: 1729-1730.
24. Cohen S, McGregor LA, Carrington S. Gamma-globulin and acquired immunity to human malaria. Nature 1961; 192: 733-737.
25. World Health Organization. Rainbow chart. Available at: (last accessed 1 July 2011).
26. Ellis RD, Sagara I, Doumbo O, Wu Y. Blood stage vaccines for Plasmodium falciparum: current status and the way forward. Hum Vaccin 2010; 6: 627-634.
27. Goodman AL, Draper SJ. Blood-stage malaria vaccines-recent progress and future challenges. Ann Trop Med Parasitol 2010; 104: 189-211.
28. Genton B, Betuela I, Felger I et al. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J Infect Dis 2002; 185: 820-827.
29. Hviid L. The role of Plasmodium falciparum variant surface antigens in protective immunity and vaccine development. Hum Vaccin 2010; 6: 84-89.
30. Avril M, Cartwright MM, Hathaway MJ, Smith JD. Induction of strain-transcendent antibodies to placental-type isolates with VAR2CSA DBL3 or DBL5 recombinant proteins. Malar J 2011; 10: e36.
31. McCarthy JS, Good MF. Whole parasite blood stage malaria vaccines: a convergence of evidence. Hum Vaccin 2010; 6: 114-123.
32. Alonso PL, Brown G, Arevalo-Herrera M et al. A research agenda to underpin malaria eradication. PLoS Med 2011; 8: e1000406.
33. Arevalo-Herrera M, Chitnis C, Herrera S. Current status of Plasmodium vivax vaccine. Hum Vaccin 2010; 6: 124-132.
34. Wu Y, Ellis RD, Shaffer D et al. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS ONE 2008; 3: e2636.
35. Dinglasan RR, Jacobs-Lorena M. Flipping the paradigm on malaria transmission-blocking vaccines. Trends Parasitol 2008; 24: 364-370.
36. Wang R, Doolan DL, Le TP et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 1998; 282: 476-480.
37. Hill AV, Reyes-Sandoval A, O'Hara G et al. Prime-boost vectored malaria vaccines: progress and prospects. Hum Vaccin 2010; 6: 78-83.
38. Hill AVS. Vaccines against malaria. Phil Trans R Soc B Biol Sci In press.
39. Bruder JT, Stefaniak ME, Patterson NB et al. Adenovectors induce functional antibodies capable of potent inhibition of blood stage malaria parasite growth. Vaccine 2010; 28: 3201-3210.
40. Kapulu MC, Biswas S, Blagborough AM, Gilbert SC, Sinden RE, Hill AVS. Viral vectored transmission blocking vaccines against Plasmodium falciparum. Malar J 2010; 9 (suppl 2): 022.
41. Bruder JT, Angov E, Limbach KJ, Richie TL. Molecular vaccines for malaria. Hum Vaccin 2010; 6: 54-77.
42. Doolan DL. Plasmodium immunomics. Int J Parasitol 2011; 41: 3-20.
43. Carlton JM, Escalante AA, Neafsey D, Volkman SK. Comparative evolutionary genomics of human malaria parasites. Trends Parasitol 2008; 24: 545-550.
44. Doolan DL, Mu Y, Unal B et al. Profiling humoral immune responses to P. falciparum infection with protein microarrays. Proteomics 2008; 8: 4680-4694.
45. van der Kolk M, De Vlas SJ, Saul A, van de Vegte-Bolmer M, Eling WM, Sauerwein RW. Evaluation of the standard membrane feeding assay (SMFA) for the determination of malaria transmission-reducing activity using empirical data. Parasitology 2005; 130 (Pt 1): 13-22.
46. Druilhe P, Spertini F, Soesoe D et al. A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum. PLoS Med 2005; 2: e344.
47. Arnold L, Tyagi RK, Meija P et al. Further improvements of the P. falciparum humanized mouse model. PLoS ONE 2011; 6: e18045.
48. Langhorne J, Buffet P, Galinski M et al. The relevance of non-human primate and rodent malaria models for humans. Malar J 2011; 10: e23.
49. Lyke KE, Laurens M, Adams M et al. Plasmodium falciparum malaria challenge by the bite of aseptic Anopheles stephensi mosquitoes: results of a randomized infectivity trial. PLoS ONE 2010; 5: e13490.
50. Sanderson F, Andrews L, Douglas AD, Hunt-Cooke A, Bejon P, Hill AV. Blood-stage challenge for malaria vaccine efficacy trials: a pilot study with discussion of safety and potential value. Am J Trop Med Hyg 2008; 78: 878-883.
51. Imoukhuede EB, Andrews L, Milligan P et al. Low-level malaria infections detected by a sensitive polymerase chain reaction assay and use of this technique in the evaluation of malaria vaccines in an endemic area. Am J Trop Med Hyg 2007; 76: 486-493.
52. Moorthy VS, Imoukhuede EB, Milligan P et al. A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults. PLoS Med 2004; 1: e33.
53. Cheru L, Wu Y, Diouf A et al. The IC(50) of anti-Pfs25 antibody in membrane-feeding assay varies among species. Vaccine 2010; 28: 4423-4429.
54. Bregu RD, Draper SJ, Hill AVS, Greenwood BM. Accelerating vaccine development and deployment: report of a royal society satellite meeting. Phil Trans R Soc B Biol Sci. In press.
55. Bousema T, Drakeley C. Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination. Clin Microbiol Rev 2011; 24: 377-410.